Ekso Bionics (NASDAQ:EKSO) CFO Buys $15,499.80 in Stock

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) CFO Jerome Wong acquired 1,308 shares of the business’s stock in a transaction on Monday, March 16th. The shares were bought at an average price of $11.85 per share, for a total transaction of $15,499.80. Following the acquisition, the chief financial officer owned 4,184 shares in the company, valued at approximately $49,580.40. This trade represents a 45.48% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Ekso Bionics Price Performance

EKSO stock opened at $10.54 on Monday. Ekso Bionics Holdings, Inc. has a one year low of $2.73 and a one year high of $13.50. The firm has a 50-day moving average of $9.95 and a two-hundred day moving average of $6.83. The firm has a market capitalization of $37.52 million, a PE ratio of -2.05 and a beta of 0.79. The company has a current ratio of 1.63, a quick ratio of 1.07 and a debt-to-equity ratio of 0.09.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on EKSO shares. HC Wainwright lowered shares of Ekso Bionics from a “buy” rating to a “neutral” rating in a research note on Wednesday, December 31st. Weiss Ratings restated a “sell (e+)” rating on shares of Ekso Bionics in a report on Monday, December 22nd. Finally, Wall Street Zen raised Ekso Bionics to a “hold” rating in a research report on Saturday, December 13th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Ekso Bionics presently has a consensus rating of “Reduce” and an average target price of $6.00.

Institutional Trading of Ekso Bionics

A number of institutional investors have recently added to or reduced their stakes in EKSO. Geode Capital Management LLC increased its stake in shares of Ekso Bionics by 68.9% during the 4th quarter. Geode Capital Management LLC now owns 25,212 shares of the company’s stock worth $218,000 after purchasing an additional 10,281 shares during the last quarter. Virtu Financial LLC acquired a new stake in shares of Ekso Bionics in the 3rd quarter valued at $57,000. Shay Capital LLC bought a new stake in Ekso Bionics in the third quarter worth $67,000. Citadel Advisors LLC bought a new stake in Ekso Bionics in the third quarter worth $198,000. Finally, Consolidated Portfolio Review Corp acquired a new position in Ekso Bionics during the third quarter worth $333,000. 6.42% of the stock is currently owned by institutional investors and hedge funds.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc (NASDAQ:EKSO) is a leading developer of wearable bionic exoskeletons designed to enhance human mobility and strength. Headquartered in Richmond, California, the company was founded in 2005 (originally as Berkeley Bionics) and completed its initial public offering in 2014. Its patented robotic systems support both rehabilitation and industrial applications by providing powered, adjustable assistance for a range of movement tasks.

In the medical sector, Ekso Bionics offers externally worn exoskeletons such as the EksoNR and EksoGT, which assist patients recovering from stroke, spinal cord injury or other neurological conditions.